Autologous dendritic cells pulsed with allogeneic tumour cell lysate induce tumour-reactive T-cell responses in patients with pancreatic cancer: A phase I study.

[1]  A. Zwinderman,et al.  Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  H. Rammensee,et al.  The Peptide Vaccine of the Future , 2021, Molecular & cellular proteomics : MCP.

[3]  Christopher R. Cabanski,et al.  CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study. , 2021, The Lancet. Oncology.

[4]  Jessica S. Yu,et al.  Multimodal mapping of the tumor and peripheral blood immune landscape in human pancreatic cancer , 2020, Nature Cancer.

[5]  S. H. van der Burg,et al.  Dendritic cell vaccination and CD40-agonist combination therapy licenses T cell-dependent antitumor immunity in a pancreatic carcinoma murine model , 2020, Journal for ImmunoTherapy of Cancer.

[6]  H. Heslop,et al.  A phase I trial targeting advanced or metastatic pancreatic cancer using a combination of standard chemotherapy and adoptively transferred nonengineered, multiantigen specific T cells in the first-line setting (TACTOPS). , 2020 .

[7]  E. Jaffee,et al.  The tumour microenvironment in pancreatic cancer — clinical challenges and opportunities , 2020, Nature Reviews Clinical Oncology.

[8]  C. la Vecchia,et al.  European cancer mortality predictions for the year 2020 with a focus on prostate cancer. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  K. Murphy,et al.  Dendritic Cell Paucity Leads to Dysfunctional Immune Surveillance in Pancreatic Cancer. , 2020, Cancer cell.

[10]  C. Dejong,et al.  Conditional Survival After Resection for Pancreatic Cancer: A Population-Based Study and Prediction Model , 2020, Annals of Surgical Oncology.

[11]  A. Jemal,et al.  Cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.

[12]  R. Hollingsworth,et al.  Turning the corner on therapeutic cancer vaccines , 2019, npj Vaccines.

[13]  Thierry Lecomte,et al.  FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer , 2018, The New England journal of medicine.

[14]  J. Aerts,et al.  Autologous Dendritic Cell Therapy in Mesothelioma Patients Enhances Frequencies of Peripheral CD4 T Cells Expressing HLA-DR, PD-1, or ICOS , 2018, Front. Immunol..

[15]  Huidong Shi,et al.  Activation of p53 in Immature Myeloid Precursor Cells Controls Differentiation into Ly6c+CD103+ Monocytic Antigen‐Presenting Cells in Tumors , 2018, Immunity.

[16]  J. Cameron,et al.  Patterns, Timing, and Predictors of Recurrence Following Pancreatectomy for Pancreatic Ductal Adenocarcinoma , 2017, Annals of surgery.

[17]  H. Hoogsteden,et al.  Autologous Dendritic Cells Pulsed with Allogeneic Tumor Cell Lysate in Mesothelioma: From Mouse to Human , 2017, Clinical Cancer Research.

[18]  J. V. Van Ginderachter,et al.  Exploiting tumor‐associated dendritic cell heterogeneity for novel cancer therapies , 2017, Journal of leukocyte biology.

[19]  G. Sica,et al.  Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1–targeted therapy in lung cancer patients , 2017, Proceedings of the National Academy of Sciences.

[20]  M. Büchler,et al.  Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial , 2017, The Lancet.

[21]  K. Hirakawa,et al.  Preoperative predictors for early recurrence of resectable pancreatic cancer , 2017, World Journal of Surgical Oncology.

[22]  I. Pastan,et al.  Mesothelin Immunotherapy for Cancer: Ready for Prime Time? , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Sandra P. Calderon-Copete,et al.  T Cell Factor 1-Expressing Memory-like CD8(+) T Cells Sustain the Immune Response to Chronic Viral Infections. , 2016, Immunity.

[24]  R. Takimoto,et al.  Immunohistochemical Analysis of WT1 Antigen Expression in Various Solid Cancer Cells. , 2016, Anticancer research.

[25]  S. Dubey,et al.  Survivin: a unique target for tumor therapy , 2016, Cancer Cell International.

[26]  D. Marx,et al.  Systemic treatment with anti-PD-1 antibody nivolumab in combination with vaccine therapy in advanced pancreatic cancer. , 2016 .

[27]  G. Honda,et al.  Proposed preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after surgical resection: A multi-center retrospective study. , 2015, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

[28]  M. McCarter,et al.  Characteristics of 10-Year Survivors of Pancreatic Ductal Adenocarcinoma. , 2015, JAMA surgery.

[29]  C. Clendenin,et al.  Exclusion of T Cells From Pancreatic Carcinomas in Mice Is Regulated by Ly6C(low) F4/80(+) Extratumoral Macrophages. , 2015, Gastroenterology.

[30]  Dirk Schadendorf,et al.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.

[31]  Lon Smith,et al.  Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors , 2015, Clinical Cancer Research.

[32]  G. Linette,et al.  Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. , 2015, The Lancet. Oncology.

[33]  D. Schadendorf,et al.  Nivolumab in previously untreated melanoma without BRAF mutation. , 2015, The New England journal of medicine.

[34]  M. Oka,et al.  Adoptive immunotherapy with MUC1-mRNA transfected dendritic cells and cytotoxic lymphocytes plus gemcitabine for unresectable pancreatic cancer , 2014, Journal of Translational Medicine.

[35]  Benjamin D. Smith,et al.  Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. , 2014, Cancer research.

[36]  G. Coukos,et al.  CD137 Accurately Identifies and Enriches for Naturally Occurring Tumor-Reactive T Cells in Tumor , 2013, Clinical Cancer Research.

[37]  I. Mellman,et al.  Oncology meets immunology: the cancer-immunity cycle. , 2013, Immunity.

[38]  C. Drake,et al.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.

[39]  E. García-Zepeda,et al.  Jak3 Is Involved in Dendritic Cell Maturation and CCR7-Dependent Migration , 2009, PloS one.

[40]  J. Donohue,et al.  Long-Term Survival After Pancreatoduodenectomy for Pancreatic Adenocarcinoma: Is Cure Possible? , 2008, Annals of surgery.

[41]  A. Moser,et al.  A phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors. , 2008, Cancer therapy.

[42]  C. Figdor,et al.  Migration of dendritic cell based cancer vaccines: in vivo veritas? , 2005, Current opinion in immunology.

[43]  R. Hruban,et al.  Mesothelin-specific CD8+ T Cell Responses Provide Evidence of In Vivo Cross-Priming by Antigen-Presenting Cells in Vaccinated Pancreatic Cancer Patients , 2004, The Journal of experimental medicine.

[44]  R. Rees,et al.  Escape from immunotherapy: possible mechanisms that influence tumor regression/progression , 2004, Cancer Immunology, Immunotherapy.

[45]  R. Lempicki,et al.  Cutting Edge: L-Selectin (CD62L) Expression Distinguishes Small Resting Memory CD4+ T Cells That Preferentially Respond to Recall Antigen , 2003, The Journal of Immunology.

[46]  F. Ronchese,et al.  Differential T Cell Function and Fate in Lymph Node and Nonlymphoid Tissues , 2002, The Journal of experimental medicine.

[47]  Lieping Chen,et al.  Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors , 1997, Nature Medicine.